HSDT - NASDAQ
Solana Company
$1.48
-15%Solana Co. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.
At a Glance
Live SnapshotSolana Company Management Team
Mr. Jeffrey S. Mathiesen CPA
Chief Financial Officer, Treasurer, Secretary & Director
Compensation
$532,644
Dr. Antonella Favit-Van Pelt M.D., Ph.D.
Chief Medical Officer
Compensation
$521,386
Mr. Dane Carl Andreeff
President, Chief Executive Officer & Director
Compensation
$586,659
Mr. Lawrence Picciano
Senior Vice President of Engineering, Quality & Regulatory Affairs
Solana Company Insider Positioning
During the last 12 months, insiders have purchased $1.04M worth of HSDT shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
106.5K
1.04M
0
0.00
+1.0M
+$1.04M
Top Buyers
Andreeff Dane
Director, 10 Percent Owner, Officer: President And Ceo
$511K
Mathiesen Jeffrey S
Director, Officer: Cfo And Treasurer
$256K
Favit-Van Pelt Antonella R.
Officer: Chief Medical Officer
$171K
Perkins Sherrie L
Director
$25K
Walter Blane
Director
$25K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $1.04M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
HSDT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 10, 2026 | May 21, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | October 14, 2025 | October 30, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | May 02, 2025 | May 23, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | March 25, 2025 | April 21, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | May 31, 2024 | June 27, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 21, 2023 | May 24, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 22, 2022 | May 23, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 23, 2021 | May 25, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | November 30, 2020 | December 28, 2020 | 2020 | |
DEF 14A DEF 14A 2020 N/A | May 11, 2020 | June 10, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.